bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figure S5 from BRCA1-Associated RING Domain-1 (BARD1) Loss and GBP1 Expression Enhance Sensitivity to DNA Damage in Ewing Sarcoma
Authors: Maurer Lisa M. , Daley Jessica D. , Mukherjee Elina , Venier Rosemarie E. , Julian Claire M. , Bailey Nathanael G. , Jacobs Michelle F. , Kumar-Sinha Chandan , Raphael Haley , Periyapatna Nivitha , Weiss Kurt , Janeway Katherine A. , Mody Rajen , Lucas Peter C. , McAllister-Lucas Linda M. , Bailey Kelly M.
Published: April 2023

Loss of GBP1 expression does not impact PSaRC318 cell migration.
Supplemental Figure S4 from BRCA1-Associated RING Domain-1 (BARD1) Loss and GBP1 Expression Enhance Sensitivity to DNA Damage in Ewing Sarcoma
Authors: Maurer Lisa M. , Daley Jessica D. , Mukherjee Elina , Venier Rosemarie E. , Julian Claire M. , Bailey Nathanael G. , Jacobs Michelle F. , Kumar-Sinha Chandan , Raphael Haley , Periyapatna Nivitha , Weiss Kurt , Janeway Katherine A. , Mody Rajen , Lucas Peter C. , McAllister-Lucas Linda M. , Bailey Kelly M.
Published: April 2023

PSaRC318 cell confluency data.
Table S4 from Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome
Authors: Silwal-Pandit Laxmi , Stålberg Stina M. , Johansson Henrik J. , Mermelekas Georgios , Lothe Inger Marie B. , Skrede Martina L. , Dalsgaard Astrid Marie , Nebdal Daniel J. H. , Helland Åslaug , Lingjærde Ole Christian , Labori Knut Jørgen , Skålhegg Bjørn S. , Lehtiö Janne , Kure Elin H.
Published: April 2023

Proteins members of modules M1-M5
Figure S5 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Authors: Ingelshed Katrine , Spiegelberg Diana , Kannan Pavitra , Påvénius Linnéa , Hacheney Jessica , Jiang Long , Eisinger Silke , Lianoudaki Danai , Lama Dilraj , Castillo Francisca , Bosdotter Cecilia , Kretzschmar Warren W. , Al-Radi Omayma , Fritz Nicolas , Villablanca Eduardo J. , Karlsson Mikael C. I. , Wermeling Fredrik , Nestor Marika , Lane David P. , Sedimbi Saikiran K.
Published: April 2023

Images radiation + Navtemadlin combination.
Figure S3 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Authors: Ingelshed Katrine , Spiegelberg Diana , Kannan Pavitra , Påvénius Linnéa , Hacheney Jessica , Jiang Long , Eisinger Silke , Lianoudaki Danai , Lama Dilraj , Castillo Francisca , Bosdotter Cecilia , Kretzschmar Warren W. , Al-Radi Omayma , Fritz Nicolas , Villablanca Eduardo J. , Karlsson Mikael C. I. , Wermeling Fredrik , Nestor Marika , Lane David P. , Sedimbi Saikiran K.
Published: April 2023

B16-F10 +/+ cells treated with increasing Navtemadlin concentrations over time.
Supplementary Figure S4 from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Authors: Konno Hiroyasu , Lin Tracey , Wu Renyi , Dai Xinchuan , Li Shou , Wang Grace , Chen Min , Li Wenying , Wang Lina , Sun Bee-Chun , Luo Zhen , Huang Tom , Chen Yuping , Zhang John , Ye Qiuping , Bellovin David , Wan Bing , Kang Lishan , Szeto Christopher , Hsu Karl , Kabbarah Omar
Published: April 2023

Supplementary Figure 4 shows confirmation of NK depletion by flow cytometer and NK levels in spleen of the mouse models.
Supplementary Figure S2 from ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
Authors: Konno Hiroyasu , Lin Tracey , Wu Renyi , Dai Xinchuan , Li Shou , Wang Grace , Chen Min , Li Wenying , Wang Lina , Sun Bee-Chun , Luo Zhen , Huang Tom , Chen Yuping , Zhang John , Ye Qiuping , Bellovin David , Wan Bing , Kang Lishan , Szeto Christopher , Hsu Karl , Kabbarah Omar
Published: April 2023

Supplementary Figure 2 shows CLDN18.2 expression in MIA-PaCa2 clones and ZL-1211-induced CDC for the MIA-PaCa2 clones.
Supplementary Figure S5 from Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis
Authors: Greer Yoshimi Endo , Hernandez Lidia , Fennell Emily M.J. , Kundu Manjari , Voeller Donna , Chari Raj , Gilbert Samuel F. , Gilbert Thomas S.K. , Ratnayake Shashikala , Tang Binwu , Hafner Markus , Chen Qingrong , Meerzaman Daoud , Iwanowicz Edwin , Annunziata Christina M. , Graves Lee M. , Lipkowitz Stanley
Published: April 2023

ONC201 RNAseq
Supplementary Figure S4 from Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis
Authors: Greer Yoshimi Endo , Hernandez Lidia , Fennell Emily M.J. , Kundu Manjari , Voeller Donna , Chari Raj , Gilbert Samuel F. , Gilbert Thomas S.K. , Ratnayake Shashikala , Tang Binwu , Hafner Markus , Chen Qingrong , Meerzaman Daoud , Iwanowicz Edwin , Annunziata Christina M. , Graves Lee M. , Lipkowitz Stanley
Published: April 2023

The effect of CPI-613 on cell viability in TNBC cell lines
Supplemental Table ST2: from Expanding the Prostate Cancer Cell Line Repertoire with ACRJ-PC28, an AR-negative Neuroendocrine Cell Line Derived From an African-Caribbean Patient
Authors: Valentine Henkel , Aiken William , Morrison Belinda , Zhao Ziran , Fowle Holly , Wasserman Jason S. , Thompson Elon , Chin Warren , Young Mark , Clarke Shannique , Gibbs Denise , Harrison Sharon , McLaughlin Wayne , Kwok Tim , Jin Fang , Campbell Kerry S. , Horvath Anelia , Thompson Rory , Lee Norman H. , Zhou Yan , Graña Xavier , Ragin Camille , Badal Simone
Published: April 2023

Supplemental Table 2: A search in the database of global cell repositories ATCC and ECACC revealed that approximately 40% of available prostate derived lines were immortalized via an exogenous source.
Supplementary Figure S11 from Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis
Authors: Greer Yoshimi Endo , Hernandez Lidia , Fennell Emily M.J. , Kundu Manjari , Voeller Donna , Chari Raj , Gilbert Samuel F. , Gilbert Thomas S.K. , Ratnayake Shashikala , Tang Binwu , Hafner Markus , Chen Qingrong , Meerzaman Daoud , Iwanowicz Edwin , Annunziata Christina M. , Graves Lee M. , Lipkowitz Stanley
Published: April 2023

The expression of CLPP and ClpP-targeted enzymes in breast cancer patients and cell lines
Supplemental Figure SF3: IHC staining on ACRJ-PC28 cells compared to positive controls. from Expanding the Prostate Cancer Cell Line Repertoire with ACRJ-PC28, an AR-negative Neuroendocrine Cell Line Derived From an African-Caribbean Patient
Authors: Valentine Henkel , Aiken William , Morrison Belinda , Zhao Ziran , Fowle Holly , Wasserman Jason S. , Thompson Elon , Chin Warren , Young Mark , Clarke Shannique , Gibbs Denise , Harrison Sharon , McLaughlin Wayne , Kwok Tim , Jin Fang , Campbell Kerry S. , Horvath Anelia , Thompson Rory , Lee Norman H. , Zhou Yan , Graña Xavier , Ragin Camille , Badal Simone
Published: April 2023

IHC staining on ACRJ-PC28 cells compared to positive controls.
Supplementary Figure S2 from Real-world Studies Link NSAID Use to Improved Overall Lung Cancer Survival
Authors: Roszik Jason , Lee J. Jack , Wu Yi-Hung , Liu Xi , Kawakami Masanori , Kurie Jonathan M. , Belouali Anas , Boca Simina M. , Gupta Samir , Beckman Robert A. , Madhavan Subha , Dmitrovsky Ethan
Published: April 2023

Supplemental Figure 2. The Kaplan-Meier analysis of overall survival and NSAID use in lung cancer cases within the MedStar-Georgetown University database (Georgetown cohort).
Supplementary Figure S1 from Real-world Studies Link NSAID Use to Improved Overall Lung Cancer Survival
Authors: Roszik Jason , Lee J. Jack , Wu Yi-Hung , Liu Xi , Kawakami Masanori , Kurie Jonathan M. , Belouali Anas , Boca Simina M. , Gupta Samir , Beckman Robert A. , Madhavan Subha , Dmitrovsky Ethan
Published: April 2023

Supplemental Figure 1 displays the studied cohorts at MD Anderson Cancer Center (MD Anderson cohort) and the MedStar-Georgetown University Hospital (Georgetown cohort).
Supplementary Table ST6 from Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer
Authors: Murphy Ryan M. , Tasoulas Jason , Porrello Alessandro , Carper Miranda B. , Tsai Yi-Hsuan , Coffey Alisha R. , Kumar Sunil , Zeng Peter YF. , Schrank Travis P. , Midkiff Bentley R. , Cohen Stephanie , Salazar Ashley H. , Hayward Michele C. , Hayes D. Neil , Olshan Andrew , Gupta Gaorav P. , Nichols Anthony C. , Yarbrough Wendell G. , Pecot Chad V. , Amelio Antonio L.
Published: April 2023

Crude 5- and 10-year survival rates by p16 cytoplasmic/nuclear status.
Supplementary Table ST2 from Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer
Authors: Murphy Ryan M. , Tasoulas Jason , Porrello Alessandro , Carper Miranda B. , Tsai Yi-Hsuan , Coffey Alisha R. , Kumar Sunil , Zeng Peter YF. , Schrank Travis P. , Midkiff Bentley R. , Cohen Stephanie , Salazar Ashley H. , Hayward Michele C. , Hayes D. Neil , Olshan Andrew , Gupta Gaorav P. , Nichols Anthony C. , Yarbrough Wendell G. , Pecot Chad V. , Amelio Antonio L.
Published: April 2023

Demographic and clinical characteristics of the study cases.
Figure S2 from Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer
Authors: Murphy Ryan M. , Tasoulas Jason , Porrello Alessandro , Carper Miranda B. , Tsai Yi-Hsuan , Coffey Alisha R. , Kumar Sunil , Zeng Peter YF. , Schrank Travis P. , Midkiff Bentley R. , Cohen Stephanie , Salazar Ashley H. , Hayward Michele C. , Hayes D. Neil , Olshan Andrew , Gupta Gaorav P. , Nichols Anthony C. , Yarbrough Wendell G. , Pecot Chad V. , Amelio Antonio L.
Published: April 2023

Validation of upregulated and downregulated genes in HPV(+) HNSC patient tumors.
Figure S4 from Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
Authors: Kurupi Richard , Floros Konstantinos V. , Jacob Sheeba , Chawla Ayesha T. , Cai Jinyang , Hu Bin , Puchalapalli Madhavi , Coon Colin M. , Khatri Rishabh , Crowther Giovanna Stein , Egan Regina K. , Murchie Ellen , Greninger Patricia , Dalton Krista M. , Ghotra Maninderjit S. , Boikos Sosipatros A. , Koblinski Jennifer E. , Harada Hisashi , Sun Yue , Morgan Iain M. , Basu Devraj , Dozmorov Mikhail G. , Benes Cyril H. , Faber Anthony C.
Published: April 2023

The mechanism of action of SHP099 inhibition
Figure S1 from Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
Authors: Kurupi Richard , Floros Konstantinos V. , Jacob Sheeba , Chawla Ayesha T. , Cai Jinyang , Hu Bin , Puchalapalli Madhavi , Coon Colin M. , Khatri Rishabh , Crowther Giovanna Stein , Egan Regina K. , Murchie Ellen , Greninger Patricia , Dalton Krista M. , Ghotra Maninderjit S. , Boikos Sosipatros A. , Koblinski Jennifer E. , Harada Hisashi , Sun Yue , Morgan Iain M. , Basu Devraj , Dozmorov Mikhail G. , Benes Cyril H. , Faber Anthony C.
Published: April 2023

Cell viability of SHP099-sensitive HNSCC cell lines
Supplementary Data S1 from Identification of Drug–Cancer Associations: A Nationwide Screening Study
Authors: Kristensen Kasper Bruun , Friis Søren , Lund Lars Christian , Hallas Jesper , Cardwell Chris R. , Andreassen Bettina K. , Habel Laurel A. , Pottegård Anton
Published: April 2023

Online Supplementary Material for publication containing additional information on covariate definitions (table S1 - S2) and statistical methods (methods S3) as well as the number of cases and examined drugs for each cancer under examination (table S4).
Table S4 from Pathway-based Approach Reveals Differential Sensitivity to E2F1 Inhibition in Glioblastoma
Authors: Alvarado Alvaro G. , Tessema Kaleab , Muthukrishnan Sree Deepthi , Sober Mackenzie , Kawaguchi Riki , Laks Dan R. , Bhaduri Aparna , Swarup Vivek , Nathanson David A. , Geschwind Daniel H. , Goldman Steven A. , Kornblum Harley I.
Published: April 2023

Normalized Enrichment Scores for each sample based on gene lists
Table S3 from Pathway-based Approach Reveals Differential Sensitivity to E2F1 Inhibition in Glioblastoma
Authors: Alvarado Alvaro G. , Tessema Kaleab , Muthukrishnan Sree Deepthi , Sober Mackenzie , Kawaguchi Riki , Laks Dan R. , Bhaduri Aparna , Swarup Vivek , Nathanson David A. , Geschwind Daniel H. , Goldman Steven A. , Kornblum Harley I.
Published: April 2023

Gene signatures associate differentially to cell cycle, cellular states, and cell identities
Supplementary Figure 1 from Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma
Authors: Andtbacka Robert H.I. , Wang Yan , Pierce Robert H. , Campbell Jean S. , Yushak Melinda , Milhem Mohammed , Ross Merrick , Niland Katie , Arbeit Robert D. , Parasuraman Sudha , Bickley Kris , Yeung Cecilia CS , Aicher Lauri D. , Smythe Kimberly S. , Gan Lu
Published: April 2023

Shared TCR TIL sequences taken from tumor biopsy of patient #5 at various timepoints.
Figure S3 from Pathway-based Approach Reveals Differential Sensitivity to E2F1 Inhibition in Glioblastoma
Authors: Alvarado Alvaro G. , Tessema Kaleab , Muthukrishnan Sree Deepthi , Sober Mackenzie , Kawaguchi Riki , Laks Dan R. , Bhaduri Aparna , Swarup Vivek , Nathanson David A. , Geschwind Daniel H. , Goldman Steven A. , Kornblum Harley I.
Published: April 2023

TCGA gene ontology analysis of clusters shows differentially enriched terms
Supplemental Table S7 from Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
Authors: Graf Ryon P. , Fisher Virginia , Creeden James , Schrock Alexa B. , Ross Jeffrey S. , Nimeiri Halla , Oxnard Geoffrey R. , Klempner Samuel J.
Published: April 2023

Restricted Mean Survival Time Difference by TMB Status in the 2L and 1L Comparative Effectiveness Cohorts. Conditional average treatment effects are defined in each TMB subgroup as the difference in expected survival time up to 3 years when treated with ICPI vs chemo. For instance, within the 1st 3 years after 2nd line treatment initiation, patients with TMB10+ would be expected to have a mean of 15.4 more months until treatment switching on ICPI compared to chemo. Bootstrap 95% confidence intervals (q025, q975) were estimated with 5000 resampling replicates.
Figure S8 from Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
Authors: Graf Ryon P. , Fisher Virginia , Creeden James , Schrock Alexa B. , Ross Jeffrey S. , Nimeiri Halla , Oxnard Geoffrey R. , Klempner Samuel J.
Published: April 2023

TMB ≥ 10 treatment predictive associations is not approximated by PD-L1 CPS ≥ 10. Cox PH models containing treatment interaction terms for both TMB ≥ 10 and PD-L1 CPS ≥ 10 are shown numerically (A) 2nd line cohort TTNT, (B) 2nd line cohort OS, and (C) sequential cohort TTNT.
Figure S7 from Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
Authors: Graf Ryon P. , Fisher Virginia , Creeden James , Schrock Alexa B. , Ross Jeffrey S. , Nimeiri Halla , Oxnard Geoffrey R. , Klempner Samuel J.
Published: April 2023

Discriminatory Power Comparison of MSI and TMB. The concordance indexes from univariable Cox PH models containing NGS-based MSI assessment, TMB, or the two in a combined multivariable Cox PH model is shown with (A) TTNT and (B) OS. Error bars indicate standard error.
Figure S4 from Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
Authors: Graf Ryon P. , Fisher Virginia , Creeden James , Schrock Alexa B. , Ross Jeffrey S. , Nimeiri Halla , Oxnard Geoffrey R. , Klempner Samuel J.
Published: April 2023

Unadjusted for known treatment assignment imbalances, patients receiving 2nd line ICPI vs. chemotherapy have more favorable outcomes when TMB ≥ 10 but not TMB < 10. Kaplan-Meier curves are unadjusted for imbalances. TTNT is shown by drug class for (A) TMB < 10, and (B) TMB ≥ 10. OS is shown by drug class for (C) TMB < 10, and (D) TMB ≥ 10. X-axis is truncated at 36 months. Overall survival estimates are left truncated (see Methods) with at-risk tables adjusted accordingly. Interaction models can be found in Supplemental Figure 8.
Figure S3 from Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
Authors: Graf Ryon P. , Fisher Virginia , Creeden James , Schrock Alexa B. , Ross Jeffrey S. , Nimeiri Halla , Oxnard Geoffrey R. , Klempner Samuel J.
Published: April 2023

Unadjusted 2nd line treatment-TMB interaction models from Supplemental Figure 2. The (A) TTNT and (B) OS interaction models are shown for for propensity adjusted analyses in Supplemental Figure 2.
Figure S2 from Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
Authors: Graf Ryon P. , Fisher Virginia , Creeden James , Schrock Alexa B. , Ross Jeffrey S. , Nimeiri Halla , Oxnard Geoffrey R. , Klempner Samuel J.
Published: April 2023

2nd line treatment-TMB interaction models from Figure 2. The (A) TTNT and (B) OS interaction models are shown for for propensity adjusted analyses in Figure 2.
Supplementary Data S4 from On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models
Authors: Savel Hélène , Barbier Sandrine , Proust-Lima Cécile , Rondeau Virginie , Thiébaut Rodolphe , Meyer-Losic Florence , Richert Laura
Published: April 2023

Residuals analysis of joint shared random effect model.
Supplementary Table 1 from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
Authors: Fanucci Kristina , Pilat Mary Jo , Shyr Derek , Shyr Yu , Boerner Scott , Li Jing , Durecki Diane , Drappatz Jan , Puduvalli Vinay , Lieberman Frank Scott , Gonzalez Javier , Giglio Pierre , Ivy S. Percy , Bindra Ranjit S. , Omuro Antonio , LoRusso Patricia
Published: April 2023

Representativeness of Study Participants
Table S2 from Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort
Authors: Glencer Alexa C. , Miller Phoebe N. , Greenwood Heather , Maldonado Rodas Cristian K. , Freimanis Rita , Basu Amrita , Mukhtar Rita A. , Brabham Case , Kim Paul , Hwang E. Shelley , Rosenbluth Jennifer M. , Hirst Gillian L. , Campbell Michael J. , Borowsky Alexander D. , Esserman Laura J.
Published: April 2023

Supplementary Table 2
Table S1 from Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort
Authors: Glencer Alexa C. , Miller Phoebe N. , Greenwood Heather , Maldonado Rodas Cristian K. , Freimanis Rita , Basu Amrita , Mukhtar Rita A. , Brabham Case , Kim Paul , Hwang E. Shelley , Rosenbluth Jennifer M. , Hirst Gillian L. , Campbell Michael J. , Borowsky Alexander D. , Esserman Laura J.
Published: April 2023

Supplementary Table 1
Supplementary Figure S9 from Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy
Authors: Paillasse Michael R. , Esquerré Michael , Bertrand Florie A. , Poussereau-Pomié Céline , Pichery Mélanie , Visentin Virgile , Gueguen-Dorbes Geneviève , Gaujarengues Florence , Barron Pauline , Badet Gaelle , Briaux Anne , Ancey Pierre-Benoit , Sibrac David , Erdociain Eric , Özcelik Dennis , Meneyrol Jérôme , Martin Valérie , Gomez-Brouchet Anne , Selves Janik , Rochaix Philippe , Battistella Maxime , Lebbé Céleste , Delord Jean-Pierre , Dol-Gleizes Frédérique , Bono Françoise , Blanc Isabelle , Alam Antoine , Hunneyball Ian , Whittaker Mark , Fons Pierre
Published: April 2023

Supplementary Figure S9 provides an overview of the mechanisms by which EVT801 exerts its anti-tumor effects
Supplementary Figure S8 from The WAVE2/miR-29/Integrin-β1 Oncogenic Signaling Axis Promotes Tumor Growth and Metastasis in Triple-negative Breast Cancer
Authors: Rana Priyanka S. , Wang Wei , Markovic Vesna , Szpendyk Justin , Chan Ernest Ricky , Sossey-Alaoui Khalid
Published: April 2023

Target Scan prediction of micoRNA target sites in the 3'UTR of WAVE2.
Figure S4 from Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy
Authors: Groeneveldt Christianne , van Ginkel Jurriaan Q. , Kinderman Priscilla , Sluijter Marjolein , Griffioen Lisa , Labrie Camilla , van den Wollenberg Diana J.M. , Hoeben Rob C. , van der Burg Sjoerd H. , ten Dijke Peter , Hawinkels Lukas J.A.C. , van Hall Thorbald , van Montfoort Nadine
Published: April 2023

Figure S4. TGF-β blockade does not impair Reo&CD3-bsAb efficacy by decreasing T-cell influx or activation.
Table S3 from Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity
Authors: Steinkamp Mara P. , Lagutina Irina , Brayer Kathryn J. , Schultz Fred , Burke Danielle , Pankratz Vernon S. , Adams Sarah F. , Hudson Laurie G. , Ness Scott A. , Wandinger-Ness Angela
Published: April 2023

Genes with lower expression in non-humanized PDX ovarian cancer samples compared to patient ovarian cancer samples
Figure S5 from Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity
Authors: Steinkamp Mara P. , Lagutina Irina , Brayer Kathryn J. , Schultz Fred , Burke Danielle , Pankratz Vernon S. , Adams Sarah F. , Hudson Laurie G. , Ness Scott A. , Wandinger-Ness Angela
Published: April 2023

HALO Quantification of immune cells
Figure S2 from Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity
Authors: Steinkamp Mara P. , Lagutina Irina , Brayer Kathryn J. , Schultz Fred , Burke Danielle , Pankratz Vernon S. , Adams Sarah F. , Hudson Laurie G. , Ness Scott A. , Wandinger-Ness Angela
Published: April 2023

Analysis of humanization in mice engrafted with CD34+ hematopoietic stem cells
Figure S1 from Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity
Authors: Steinkamp Mara P. , Lagutina Irina , Brayer Kathryn J. , Schultz Fred , Burke Danielle , Pankratz Vernon S. , Adams Sarah F. , Hudson Laurie G. , Ness Scott A. , Wandinger-Ness Angela
Published: April 2023

Gene expression analysis of OvCa samples
Supplemental Table 2 from Association Between Recreational Physical Activity and mTOR Signaling Pathway Protein Expression in Breast Tumor Tissue
Authors: Cheng Ting-Yuan David , Zhang Runzhi , Gong Zhihong , Qin Bo , Cannioto Rikki A. , Datta Susmita , Zhang Weizhou , Omilian Angela R. , Yao Song , Khoury Thaer , Hong Chi-Chen , Bandera Elisa V. , Ambrosone Christine B.
Published: April 2023

Supplemental Table 2 shows protein expression in breast cancer tissue and paired adjacent normal tissue.
Figure S2 from Detection of MET polysomy by next-generation sequencing and its clinical relevance for MET inhibitors
Authors: Sun Boyang , Qiu Tian , Zeng Xiaoling , Duan Jianchun , Bai Hua , Xu Jiachen , Li Jin , Li Junling , Hao Xuezhi , Liu Yutao , Lin Lin , Wang Hongyu , Zhang Xin , Zhong Jia , Wang Jie , Ying Jianming , Wang Zhijie
Published: April 2023

The detection process using NGS of the study.
Supplemental Table 10 from Association Between Recreational Physical Activity and mTOR Signaling Pathway Protein Expression in Breast Tumor Tissue
Authors: Cheng Ting-Yuan David , Zhang Runzhi , Gong Zhihong , Qin Bo , Cannioto Rikki A. , Datta Susmita , Zhang Weizhou , Omilian Angela R. , Yao Song , Khoury Thaer , Hong Chi-Chen , Bandera Elisa V. , Ambrosone Christine B.
Published: April 2023

Supplemental Table 10 reported stratified analysis for women with and without history of diabetes.
Supplementary Tables S1 and S2 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
Authors: Lin Cindy , Garcia-Gerique Laura , Bonner Erin E. , Mastio Jerome , Rosenwasser Matthew , Cruz Zachary , Lawler Michael , Bernabei Luca , Muthumani Kar , Liu Qin , Poncz Mortimer , Vogl Thomas , Törngren Marie , Eriksson Helena , Vogl Dan T. , Gabrilovich Dmitry I. , Nefedova Yulia
Published: April 2023

Supplementary Table 1. Antibodies used in the study.

Supplementary Table 2. Primers used in the study.
Figure S7 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
Authors: Lin Cindy , Garcia-Gerique Laura , Bonner Erin E. , Mastio Jerome , Rosenwasser Matthew , Cruz Zachary , Lawler Michael , Bernabei Luca , Muthumani Kar , Liu Qin , Poncz Mortimer , Vogl Thomas , Törngren Marie , Eriksson Helena , Vogl Dan T. , Gabrilovich Dmitry I. , Nefedova Yulia
Published: April 2023

Effect of TQ in S100A9KO MM-bearing mice.
Figure S3 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Authors: Matos Israel , Barvalia Maunish , Chehal Manreet K. , Robertson A. Gordon , Kulic Iva , Silva Jessica A.F.D. , Ranganathan Abhinandan , Short Amy , Huang Yu-Hsuan , Long Erin , Priatel John J. , Dhanji Salim , Nelson Brad H. , Krebs Danielle L. , Harder Kenneth W.
Published: April 2023

Supplementary Figure S3 shows deep phenotyping of Neut/MDSCs and B cells in the bone marrow of mice bearing MT or MTG-CSF-/- tumors, using FlowSOM applied in tSNE maps.
Figure S1 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Authors: Matos Israel , Barvalia Maunish , Chehal Manreet K. , Robertson A. Gordon , Kulic Iva , Silva Jessica A.F.D. , Ranganathan Abhinandan , Short Amy , Huang Yu-Hsuan , Long Erin , Priatel John J. , Dhanji Salim , Nelson Brad H. , Krebs Danielle L. , Harder Kenneth W.
Published: April 2023

Supplementary Figure S1 shows the characterization of MT and MTG-CSF-/- cell lines and tumors, including surface protein expression, tumor volume/weight, and immune cell subset content. Composition of immune cells in blood and spleen of MT and MTG-CSF-/- mice is also shown.
Supplemental Figure 5 from Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma
Authors: Gavrielatou Niki , Vathiotis Ioannis A. , Aung Thazin Nwe , Shafi Saba , Burela Sneha , Fernandez Aileen I. , Moutafi Myrto , Burtness Barbara A. , Economopoulou Panagiota , Anastasiou Maria , Foukas Periklis , Psyrri Amanda , Rimm David L.
Published: April 2023

association of B2M mRNA expression with OS in the non-immunotherapy treated TCGA HNSCC ccohort
Table S2 from IOA-244 is a non-ATP-competitive, highly selective, tolerable phosphoinositide 3-kinase delta inhibitor that targets solid tumors and breaks immune tolerance
Authors: Johnson Zoë , Tarantelli Chiara , Civanelli Elisa , Cascione Luciano , Spriano Filippo , Fraser Amy , Shah Pritom , Nomanbhoy Tyzoon , Napoli Sara , Rinaldi Andrea , Niewola-Staszkowska Karolina , Lahn Michael , Perrin Dominique , Wenes Mathias , Migliorini Denis , Bertoni Francesco , van der Veen Lars , Di Conza Giusy
Published: April 2023

Table showing values of microsomal stability of IOA-244
Supplemental Figure 3 from Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma
Authors: Gavrielatou Niki , Vathiotis Ioannis A. , Aung Thazin Nwe , Shafi Saba , Burela Sneha , Fernandez Aileen I. , Moutafi Myrto , Burtness Barbara A. , Economopoulou Panagiota , Anastasiou Maria , Foukas Periklis , Psyrri Amanda , Rimm David L.
Published: April 2023

correlation of b2m protein with B2M mRNA expression in Athens cohort. Association of B2M mRNA levels with response and disease control
Figure S2 from IOA-244 is a non-ATP-competitive, highly selective, tolerable phosphoinositide 3-kinase delta inhibitor that targets solid tumors and breaks immune tolerance
Authors: Johnson Zoë , Tarantelli Chiara , Civanelli Elisa , Cascione Luciano , Spriano Filippo , Fraser Amy , Shah Pritom , Nomanbhoy Tyzoon , Napoli Sara , Rinaldi Andrea , Niewola-Staszkowska Karolina , Lahn Michael , Perrin Dominique , Wenes Mathias , Migliorini Denis , Bertoni Francesco , van der Veen Lars , Di Conza Giusy
Published: April 2023

Target engagement kinase tree
Supplementary Table 1 from Induction of PARP7 Creates a Vulnerability for Growth
Inhibition by RBN2397 in Prostate Cancer Cells
Authors: Yang Chunsong , Wierbilowicz Krzysztof , Dworak Natalia M , Bae Song Yi , Tengse Sachi B , Abianeh Nicki , Drake Justin M , Abbas Tarek , Ratan Aakrosh , Wotton David , Paschal Bryce M
Published: April 2023

Supplementary Table 1: RBN2397 growth effects in prostate cencer cell lines
Supplementary Figure 5 from Induction of PARP7 Creates a Vulnerability for Growth
Inhibition by RBN2397 in Prostate Cancer Cells
Authors: Yang Chunsong , Wierbilowicz Krzysztof , Dworak Natalia M , Bae Song Yi , Tengse Sachi B , Abianeh Nicki , Drake Justin M , Abbas Tarek , Ratan Aakrosh , Wotton David , Paschal Bryce M
Published: April 2023

FACS analysis of NCI-H660 cells for detection of necrosis and apoptosis
Supplementary Figure S8 from Whole-genome and epigenomic landscapes of malignant gastrointestinal stromal tumors harboring KIT exon 11 557–558 deletion mutations
Authors: Ohshima Keiichi , Nagashima Takeshi , Fujiya Keiichi , Hatakeyama Keiichi , Watanabe Yuko , Morimoto Kimiko , Kamada Fukumi , Shimoda Yuji , Ohnami Sumiko , Naruoka Akane , Serizawa Masakuni , Ohnami Shumpei , Kenmotsu Hirotsugu , Shiomi Akio , Tsubosa Yasuhiro , Bando Etsuro , Sugiura Teiichi , Sugino Takashi , Terashima Masanori , Uesaka Katsuhiko , Urakami Kenichi , Akiyama Yasuto , Yamaguchi Ken
Published: April 2023

Functional enrichment analysis of the differentially expressed genes in malignant GISTs with KIT Δ557–558.
Supplementary Figure S10 from Whole-genome and epigenomic landscapes of malignant gastrointestinal stromal tumors harboring KIT exon 11 557–558 deletion mutations
Authors: Ohshima Keiichi , Nagashima Takeshi , Fujiya Keiichi , Hatakeyama Keiichi , Watanabe Yuko , Morimoto Kimiko , Kamada Fukumi , Shimoda Yuji , Ohnami Sumiko , Naruoka Akane , Serizawa Masakuni , Ohnami Shumpei , Kenmotsu Hirotsugu , Shiomi Akio , Tsubosa Yasuhiro , Bando Etsuro , Sugiura Teiichi , Sugino Takashi , Terashima Masanori , Uesaka Katsuhiko , Urakami Kenichi , Akiyama Yasuto , Yamaguchi Ken
Published: April 2023

Expression levels for genes involved in recurrently detected SVs.
Table S5 from Predicting Cancer Risk from Germline Whole-exome Sequencing Data Using a Novel Context-based Variant Aggregation Approach
Authors: Guan Zoe , Begg Colin B. , Shen Ronglai
Published: April 2023

Table S5: Significant predictors from individual association analyses based on SNP array data. The significance threshold for each cancer type was 0.05/2824 (2824 predictors were tested for each cancer type).
Supplementary Data S1 from Whole-genome and epigenomic landscapes of malignant gastrointestinal stromal tumors harboring KIT exon 11 557–558 deletion mutations
Authors: Ohshima Keiichi , Nagashima Takeshi , Fujiya Keiichi , Hatakeyama Keiichi , Watanabe Yuko , Morimoto Kimiko , Kamada Fukumi , Shimoda Yuji , Ohnami Sumiko , Naruoka Akane , Serizawa Masakuni , Ohnami Shumpei , Kenmotsu Hirotsugu , Shiomi Akio , Tsubosa Yasuhiro , Bando Etsuro , Sugiura Teiichi , Sugino Takashi , Terashima Masanori , Uesaka Katsuhiko , Urakami Kenichi , Akiyama Yasuto , Yamaguchi Ken
Published: April 2023

SVs identified in the 30 GIST cases in our study cohort.
Figure SF7 from Plexin-B1 Mutation Drives Metastasis in Prostate Cancer Mouse Models
Authors: Shorning Boris , Trent Neil , Griffiths David F. , Worzfeld Thomas , Offermanns Stefan , Smalley Matthew J. , Williamson Magali
Published: April 2023

Metastatic deposits in Ptenfl/flp53fl/flPLXNB1P1597L mice
Figure SF3 from Plexin-B1 Mutation Drives Metastasis in Prostate Cancer Mouse Models
Authors: Shorning Boris , Trent Neil , Griffiths David F. , Worzfeld Thomas , Offermanns Stefan , Smalley Matthew J. , Williamson Magali
Published: April 2023

Metastases in Ptenfl/flKrasG12V mice
Supplementary Figure S3 from Toll-like Receptor Signaling–deficient Cells Enhance Antitumor Activity of Cell-based Immunotherapy by Increasing Tumor Homing
Authors: Morales-Molina Alvaro , Rodriguez-Milla Miguel Ángel , Gambera Stefano , Cejalvo Teresa , de Andrés Belén , Gaspar María-Luisa , García-Castro Javier
Published: April 2023

MSCs TLR4−/− do not induce any antitumor effect in vivo by itself
Figure SF1 from Plexin-B1 Mutation Drives Metastasis in Prostate Cancer Mouse Models
Authors: Shorning Boris , Trent Neil , Griffiths David F. , Worzfeld Thomas , Offermanns Stefan , Smalley Matthew J. , Williamson Magali
Published: April 2023

Generation of PLXNB1WT and PLXNB1P1597L mice
Supplementary Figure S6 from Structurally complex osteosarcoma genomes exhibit limited heterogeneity within individual tumors and across evolutionary time
Authors: Rajan Sanjana , Zaccaria Simone , Cannon Matthew , Cam Maren , Gross Amy C , Raphael Benjamin J , Roberts Ryan D.
Published: April 2023

TP53 copy number in single-cell data
Figure S5 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
Authors: Sun Boyang , Qiu Tian , Zeng Xiaoling , Duan Jianchun , Bai Hua , Xu Jiachen , Li Jin , Li Junling , Hao Xuezhi , Liu Yutao , Lin Lin , Wang Hongyu , Zhang Xin , Zhong Jia , Wang Jie , Ying Jianming , Wang Zhijie
Published: April 2023

One MET-FISH-negative patient was classified as having MET polysomy by NGS
Data from Race-associated Molecular Changes in Gynecologic Malignancies
Authors: Asare Amma , Yao Hui , Lara Olivia D. , Wang Ying , Zhang Lin , Sood Anil K.
Published: April 2023

The difference in cancer morbidity and mortality between individuals of different racial groups is complex. Health disparities provide a framework to explore potential connections between poor outcomes and individuals of different racial backgrounds. This study identifies genomic changes in African American patients with gynecologic malignancies, a population with well-established disparities in outcomes. Our data explore whether social health disparities might mediate interactions between the environment and tumor epigenomes and genomes that can be identified. Using The Cancer Genetic Ancestry Atlas, which encodes data from The Cancer Genome Atlas by ancestry and allows for systematic analyses of sequencing data by racial group, we performed large-scale, comparative analyses to identify novel targets with alterations in methylation, transcript, and miRNA expression between tumors from women of European American or African American racial groups across all gynecologic malignancies. We identify novel discrete genomic changes in these complex malignancies and suggest a framework for identifying novel therapeutic targets for future investigation.
Significance:
Common genetic changes in breast, ovarian, cervix, and uterine tumors can be identified in African American patients. Understanding why these changes occur may help improve outcomes for all patients with cancer.
Data from World Trade Center Dust Exposure Promotes Cancer in PTEN-deficient Mouse Prostates
Authors: Wang Lin , Xu Yitian , Zhang Licheng , Kang Kyeongah , Kobryn Andriy , Portman Kensey , Gordon Ronald E , Pan Ping-Ying , Taioli Emanuela , Aaronson Stuart A , Chen Shu-Hsia , Mulholland David J
Published: April 2023

During the 9/11 attacks, individuals were exposed to World Trade Center (WTC) dust which contained a complex mixture of carcinogens. Epidemiologic studies have revealed the increased incidence of prostate and thyroid cancer in WTC survivors and responders. While reports have shown that WTC-dust associates with the increased prevalence of inflammatory-related disorders, studies to date have not determined whether this exposure impacts cancer progression. In this study, we have used genetically engineered mouse (GEM) models with prostate-specific deletion of the PTEN tumor suppressor to study the impact of WTC-dust exposure on deposition of dust particles, inflammation, and cancer progression. In normal C57/BL6 mice, dust exposure increased cellular expression of inflammatory genes with highest levels in the lung and peripheral blood. In normal and tumor-bearing GEM mice, increased immune cell infiltration to the lungs was observed. Pathologic evaluation of mice at different timepoints showed that WTC-dust exposure promoted PI3K-AKT activation, increased epithelial proliferation and acinar invasion in prostates with heterozygous and homozygous Pten loss. Using autochthonous and transplant GEM models of prostate cancer, we demonstrated that dust exposure caused reduced survival as compared with control cohorts. Finally, we used imaging mass cytometry to detect elevated immune cell infiltration and cellular expression of inflammatory markers in prostate tumors isolated from human WTC survivors. Collectively, our study shows that chronic inflammation, induced by WTC dust exposure, promotes more aggressive cancer in genetically predisposed prostates and potentially in patients.
Significance:
We provide the first evidence that exposure to WTC dust promotes prostate cancer progression. These data may impact the diagnoses, clinical management, and treatment of responders who have or will develop cancer.
Data from A Genome-Wide Gene-Based Gene–Environment Interaction Study of Breast Cancer in More than 90,000 Women
Authors: Wang Xiaoliang , Chen Hongjie , Kapoor Pooja Middha , Su Yu-Ru , Bolla Manjeet K. , Dennis Joe , Dunning Alison M. , Lush Michael , Wang Qin , Michailidou Kyriaki , Pharoah Paul D.P. , Hopper John L. , Southey Melissa C. , Koutros Stella , Freeman Laura E. Beane , Stone Jennifer , Rennert Gad , Shibli Rana , Murphy Rachel A. , Aronson Kristan , Guénel Pascal , Truong Thérèse , Teras Lauren R. , Hodge James M. , Canzian Federico , Kaaks Rudolf , Brenner Hermann , Arndt Volker , Hoppe Reiner , Lo Wing-Yee , Behrens Sabine , Mannermaa Arto , Kosma Veli-Matti , Jung Audrey , Becher Heiko , Giles Graham G. , Haiman Christopher A. , Maskarinec Gertraud , Scott Christopher , Winham Stacey , Simard Jacques , Goldberg Mark S. , Zheng Wei , Long Jirong , Troester Melissa A. , Love Michael I. , Peng Cheng , Tamimi Rulla , Eliassen Heather , García-Closas Montserrat , Figueroa Jonine , Ahearn Thomas , Yang Rose , Evans D. Gareth , Howell Anthony , Hall Per , Czene Kamila , Wolk Alicja , Sandler Dale P. , Taylor Jack A. , Swerdlow Anthony J. , Orr Nick , Lacey James V. , Wang Sophia , Olsson Håkan , Easton Douglas F. , Milne Roger L. , Hsu Li , Kraft Peter , Chang-Claude Jenny , Lindström Sara
Published: April 2023

Genome-wide association studies (GWAS) have identified more than 200 susceptibility loci for breast cancer, but these variants explain less than a fifth of the disease risk. Although gene–environment interactions have been proposed to account for some of the remaining heritability, few studies have empirically assessed this.

We obtained genotype and risk factor data from 46,060 cases and 47,929 controls of European ancestry from population-based studies within the Breast Cancer Association Consortium (BCAC). We built gene expression prediction models for 4,864 genes with a significant (P < 0.01) heritable component using the transcriptome and genotype data from the Genotype-Tissue Expression (GTEx) project. We leveraged predicted gene expression information to investigate the interactions between gene-centric genetic variation and 14 established risk factors in association with breast cancer risk, using a mixed-effects score test.

After adjusting for number of tests using Bonferroni correction, no interaction remained statistically significant. The strongest interaction observed was between the predicted expression of the C13orf45 gene and age at first full-term pregnancy (PGXE = 4.44 × 10−6).

In this transcriptome-informed genome-wide gene–environment interaction study of breast cancer, we found no strong support for the role of gene expression in modifying the associations between established risk factors and breast cancer risk.

Our study suggests a limited role of gene–environment interactions in breast cancer risk.
Data from Prospective Associations of Hemoglobin A1c and c-peptide with Risk of Diabetes-related Cancers in the Cancer Prevention Study-II Nutrition Cohort
Authors: Campbell Peter T. , Newton Christina C. , Jacobs Eric J. , McCullough Marjorie L. , Wang Ying , Rees-Punia Erika , Guinter Mark A. , Murphy Neil , Koshiol Jill , Dehal Ahmed N. , Rohan Thomas , Strickler Howard , Petrick Jessica , Gunter Marc , Zhang Xuehong , McGlynn Katherine A. , Pollak Michael , Patel Alpa V. , Gapstur Susan M.
Published: April 2023

Self-reported type 2 diabetes mellitus (T2DM) is a risk factor for many cancers, suggesting its pathology relates to carcinogenesis. We conducted a case-cohort study to examine associations of hemoglobin A1c (HbA1c) and c-peptide with cancers associated with self-reported T2DM. This study was drawn from a prospective cohort of 32,383 women and men who provided blood specimens at baseline: c-peptide and HbA1c were assessed in 3,000 randomly selected participants who were cancer-free-at-baseline and an additional 2,281 participants who were cancer-free-at-baseline and subsequently diagnosed with incident colorectal, liver, pancreatic, female breast, endometrial, ovarian, bladder, or kidney cancers. Weighted Cox regression models estimated HRs and 95% confidence intervals (CI), adjusted for covariates. c-peptide was associated with higher risk of liver cancer [per SD HR: 1.80; 95% CI: 1.32–2.46]. HbA1c was associated with higher risk of pancreatic cancer (per SD HR: 1.21; 95% CI: 1.05–1.40) and with some suggestion of higher risks for all-cancers-of-interest (per SD HR: 1.05; 95% CI: 0.99–1.11) and colorectal (per SD HR: 1.09; 95% CI: 0.98–1.20), ovarian (per SD HR: 1.18; 95% CI: 0.96–1.45) and bladder (per SD HR: 1.08; 95% CI: 0.96–1.21) cancers. Compared with no self-reported T2DM and HbA1c < 6.5% (reference group), self-reported T2DM and HbA1c < 6.5% (i.e., T2DM in good glycemic control) was not associated with risk of colorectal cancer, whereas it was associated with higher risks of all-cancers-of-interest combined (HR: 1.28; 95% CI: 1.01–1.62), especially for breast and endometrial cancers. Additional large, prospective studies are needed to further explore the roles of hyperglycemia, hyperinsulinemia, and related metabolic traits with T2DM-associated cancers to better understand the mechanisms underlying the self-reported T2DM-cancer association and to identify persons at higher cancer risk.
Significance:
The results from this study suggest that HbA1c and c-peptide, markers of hyperglycemia and hyperinsulinemia respectively, are associated with certain cancers, though people with diabetes may be at increased risk of these cancers, perhaps other than colorectal, even when their glucose is well controlled.
Data from Circulating IgA Antibodies Against Fusobacterium nucleatum Amyloid Adhesin FadA are a Potential Biomarker for Colorectal Neoplasia
Authors: Baik Jung Eun , Li Li , Shah Manish A. , Freedberg Daniel E. , Jin Zhezhen , Wang Timothy C. , Han Yiping W.
Published: April 2023

Fusobacterium nucleatum (Fn) is a gram-negative oral anaerobe and prevalent in colorectal cancer. Fn encodes a unique amyloid-like adhesin, FadA complex (FadAc), consisting of intact pre-FadA and cleaved mature FadA, to promote colorectal cancer tumorigenesis. We aimed to evaluate circulating anti-FadAc antibody levels as a biomarker for colorectal cancer. Circulating anti-FadAc IgA and IgG levels were measured by ELISA in two study populations. In study 1, plasma samples from patients with colorectal cancer (n = 25) and matched healthy controls (n = 25) were obtained from University Hospitals Cleveland Medical Center. Plasma levels of anti-FadAc IgA were significantly increased in patients with colorectal cancer (mean ± SD: 1.48 ± 1.07 μg/mL) compared with matched healthy controls (0.71 ± 0.36 μg/mL; P = 0.001). The increase was significant in both early (stages I and II) and advanced (stages III and IV) colorectal cancer. In study 2, sera from patients with colorectal cancer (n = 50) and patients with advanced colorectal adenomas (n = 50) were obtained from the Weill Cornell Medical Center biobank. Anti-FadAc antibody titers were stratified according to the tumor stage and location. Similar as study 1, serum levels of anti-FadAc IgA were significantly increased in patients with colorectal cancer (2.06 ± 1.47 μg/mL) compared with patients with colorectal adenomas (1.49 ± 0.99 μg/mL; P = 0.025). Significant increase was limited to proximal cancers, but not distal tumors. Anti-FadAc IgG was not increased in either study population, suggesting that Fn likely translocates through the gastrointestinal tract and interact with colonic mucosa. Anti-FadAc IgA, but not IgG, is a potential biomarker for early detection of colorectal neoplasia, especially for proximal tumors.
Significance:
Fn, an oral anaerobe highly prevalent in colorectal cancer, secretes the amyloid-like FadAc to promote colorectal cancer tumorigenesis. We report that circulating levels of anti-FadAc IgA, but not IgG, are increased in patients with both early and advanced colorectal cancer compared with the healthy controls, and especially in those with proximal colorectal cancer. Anti-FadAc IgA may be developed into a serological biomarker for early detection of colorectal cancer.
Neoadjuvant Management of Adenocarcinoma of the Esophagus and Esophagogastric Junction: Review of Randomized Evidence and Definition of Optimum Treatment Algorithm
Authors: Hingorani Mohan , Goody Rebecca , Bozas Georgios , Zahid Khwaja , Mitton David James , Jain Prashant , Wong Vincent , Roy Rajarshi
Published: April 2023

Background: Neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) are accepted standards of care for the management of adenocarcinoma of the esophagus and gastroesophageal junction. Summary: The MRC-OEO2 study established the role of 2 cycles of neoadjuvant cisplatin/fluoropyrimidine. More recently, the FLOT-AIO4 study demonstrated the superiority of perioperative FLOT chemotherapy (5FU, oxaliplatin, and docetaxel) compared to ECX (epirubicin, cisplatin, and capecitabine) regime. The results from the pivotal CROSS study established neoadjuvant CRT as a new standard of care in OG cancer. The survival benefits observed in FLOT and CROSS studies are similar [FLOT – hazard ratio 0.75 (0.62–0.92); CROSS – 0.741 (0.55–0.98)]. Key Messages: Both nCT and nCRT have been shown to be associated with survival benefit compared to surgery alone. We have performed a comprehensive review of the available evidence to define the optimum treatment algorithm and identify specific patient sub-groups who may be appropriate for the use of one or more of these neoadjuvant options.